Signals
Down Syndrome Cannot Stay Outside Alzheimer’s Trials
Alnylam has launched a Phase 2 study of mivelsiran in Down syndrome-associated Alzheimer’s disease. The trial is early, but the access issue is already mature: a high-risk population cannot remain peripheral to Alzheimer’s research.
Europe’s AMR Strategy Depends on the Lab Result Being Right
Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies
Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem
Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
AMR Stewardship Starts Before the Antibiotic Is Prescribed
HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care
GIST Care Looks Beyond First-Generation KIT Control
World Cup Health Guidance Turns Football Into a Public-Health Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.